Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Armstrong Wants Extra Year To Develop Inhaler Without Epinephrine

This article was originally published in The Tan Sheet

Executive Summary

Generic manufacturer Armstrong Pharmaceuticals is asking FDA to delay for a year until 2011 the agency's proposed rule that would force epinephrine-containing metered-dose inhalers off the market
Advertisement

Related Content

Armstrong’s Primatene Mist Inhaler Has 2011 Deadline To Exit The Market
Armstrong’s Primatene Mist Inhaler Has 2011 Deadline To Exit The Market
Armstrong’s Primatene Mist Inhaler Has 2011 Deadline To Exit The Market
Primatene Mist To Be Unavailable After 2010 – Proposed Rule
Primatene Mist To Be Unavailable After 2010 – Proposed Rule
Primatene Mist Availability Not “Essential,” Advisory Panel Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS101169

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel